Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H26IN3O7 |
Molecular Weight | 531.3312 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNCC1=CC=C([123I])C=C1)C(O)=O)C(O)=O
InChI
InChIKey=OXUUJYOSVPMNKP-ZANJDRPYSA-N
InChI=1S/C19H26IN3O7/c20-13-6-4-12(5-7-13)11-21-10-2-1-3-14(17(26)27)22-19(30)23-15(18(28)29)8-9-16(24)25/h4-7,14-15,21H,1-3,8-11H2,(H,24,25)(H,26,27)(H,28,29)(H2,22,23,30)/t14-,15-/m0/s1/i20-4
Iofolastat I-123 is a radiolabeled iodobenzylamine derivative developed by Molecular Insight Pharmaceuticals, Inc as molecular imaging pharmaceuticals for prostate cancer. Iofolastat I123 selectively binds prostate-specific membrane antigen (PSMA), which allows imaging of PSMA-expressing prostate cancer cells. In Phase I clinical trial Iofolastat I-123 localized to lesions in bone and soft tissue that correlated with radiologic evidence of metastatic prostate cancer. Minimal uptake of one of Iofolastat I-123 as seen in the prostate gland of healthy volunteers, suggesting the possibility of visualizing disease in that organ.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23303962
370 MBq (10 mCi)
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9457
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
DB12514
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL496748
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
25194767
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
949575-24-0
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
AQF0A29T2V
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
300000037062
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
XX-33
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
C78827
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY | |||
|
DTXSID00241698
Created by
admin on Sat Dec 16 01:40:28 GMT 2023 , Edited by admin on Sat Dec 16 01:40:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY